Komori
Ono Pharmaceutical (4528) · TargetAdvanced

Achievement of carbon neutrality for Scope 1 and 2 and bringing forward the target for zero greenhouse gas emissions

First written in FY2023. 3 of 4 entries say "Advanced", first in FY2024. Latest entry: FY2026.

4entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2023AdvancedFY2024 – FY20262023: 120232024: 120242025: 120252026: 12026
Same theme, other companies
GHG emissions (Scopes 1–3): calculation, emissions-reduction target-setting and renewable energy procurementA theme 999 companies write about · 7 as a headwind · 1055 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 191 companies compared. The sentences above are computed from all 191.Comparing 200 of the theme's 1063 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「In 2025, we expect to achieve carbon neutrality for greenhouse gas emissions from our own operations (Scope 1+2), as well as a 100% renewable energy ratio for purchased electricity at our own business locations.」

    For fiscal 2024, we disclosed Scope 1 and 2 emissions of 8.9 thousand t-CO2, a 70.3% reduction from fiscal 2017, Scope 3 emissions of 100.5 thousand t-CO2, and a renewable energy ratio of 93.2% for purchased electricity, indicating that the 2025 target is expected to be achieved.
  2. FY2025AdvancedAnnual report

    「We aim to achieve carbon neutrality for our own emissions in 2025 and have brought forward our target for zero greenhouse gas emissions from our own operations from 2050 to 2035. We are also working toward supplying 100% of purchased electricity from renewable energy sources in 2025.」

    The targets of zero Scope 1 and 2 emissions by 2035, a 30% reduction in Scope 3 emissions by 2030 and a 60% reduction by 2050, and 100% renewable energy for purchased electricity in 2025 were disclosed, together with actual Scope 1 and 2 emissions of 16.0 thousand t-CO2 and a renewable energy ratio of 48.5%.
  3. FY2024AdvancedAnnual report

    「We aim to achieve carbon neutrality for our own emissions in 2025 and have brought forward our target for zero greenhouse gas emissions from our own operations from 2050 to 2035. We are also working toward supplying 100% of purchased electricity from renewable energy sources in 2025.」

    The targets of carbon neutrality in 2025, zero Scope 1 and 2 emissions in 2035, and 100% renewable energy for purchased electricity in 2025 were reiterated, together with actual Scope 1 and 2 emissions of 18.4 thousand t-CO2 and a renewable energy ratio of 25.1%.
  4. FY2023First statedAnnual report

    「We aim to achieve carbon neutrality for our own emissions (Scope 1+2) in 2025, meaning net zero through carbon offsets, and have brought forward our target for zero greenhouse gas emissions from our own operations from 2050 to 2035.」

    The targets and deadlines for net-zero Scope 1 and 2 emissions in 2025 and zero emissions from our own operations in 2035 were presented independently for the first time, replacing the previous environmental policy of ECO VISION 2050.
Moved together

"Strengthening Oversight Functions through the Board of Directors, Board of Corporate Auditors and Outside Officers" moved the same way as this thread, in the same document, in 3 of its 4 moves.

333333★123456
  1. ★This thread
  2. 1Strengthening Oversight Functions through the Board of Directors, Board of Corporate Auditors and Outside Officers3×
  3. 2Long-term enhancement of corporate value and alignment of interests with shareholders3×
  4. 3Expansion of the development pipeline and continued launches of new drugs3×
  5. 4In-Licensing Promising New Drug Candidate Compounds and Accelerating Clinical Trials3×
  6. 5Global business expansion and international launches3×
  7. 6Strengthening the R&D organization by incorporating the world's most advanced expertise and technologies3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Ono Pharmaceutical's next results are scheduled for 2026-10-29. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Achievement of carbon neutrality for Scope 1 and 2 and bringing forward the target for zero greenhouse gas emissions | ONO PHARMACEUTICAL CO.,LTD. (4528) | Komori